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Current Status of Partial Nephrectomy for Renal Mass
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The standard treatment for a small mass has shifted from radical nephrectomy to parti-
al nephrectomy. The benefits of partial nephrectomy, including preserving renal func-
tion, prolonging overall survival, preventing postoperative chronic kidney disease, and 
reducing cardiovascular events, have been discussed in many studies. With the accu-
mulation of surgeons’ experience and simplification of the operative procedures, the 
warm ischemic time has become shorter despite the indication of tumor size becoming 
larger. With the help of intraoperative ultrasound, partial nephrectomy can be per-
formed for an endophytic renal mass. Recently, laparoscopic partial nephrectomy has 
become well indicated for most renal tumors in many centers with advanced laparo-
scopic expertise. Open partial nephrectomy remains indicated for complex tumors. 
With technical innovation, robotic partial nephrectomy shows at least comparable peri-
operative outcomes with a benefit for challenging cases. Laparoendoscopic single-site 
partial nephrectomy has recently been tried in limited indications and seems to be 
feasible.
Key Words: Kidney neoplasms; Minimal invasive surgery; Nephrectomy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial 
License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, 
distribution, and reproduction in any medium, provided the original work is properly cited.
Article History:
received 31 January, 2011
accepted 14 March, 2011
Corresponding Author:
Seong Il Seo
Department of Urology, Samsung 
Medical Center, Sungkyunkwan 
University School of Medicine, 50, 
Irwon-dong, Gangnam-gu, Seoul 
135-710, Korea
TEL: +82-2-3410-3556
FAX: +82-2-3410-6992
E-mail: siseo@skku.edu
INTRODUCTION
Over 200,000 new cases of kidney cancer are diagnosed in 
the world each year [1]. The number of cases has been grow-
ing in Korea as well as in Europe and in the United States. 
According to a report of the Korea National Statistical 
Office, 2,846 new cases occurred in 2007. 
　The increase in kidney cancer may be attributed to the 
development of imaging modalities, which allow early de-
tection of the tumor. Generally, these incidentally detected 
tumors tend to be smaller and of a lower stage. The stand-
ard treatment for a small mass has shifted from radical 
nephrectomy (RN) to partial nephrectomy (PN). The ad-
vantage of PN is not only excellent oncologic outcome but 
also better long-term preservation of renal function, lead-
ing to better overall survival. 
　With the pursuing of minimally invasive techniques and 
the rapid evolution of laparoscopic techniques, the surgical 
modality of PN has expanded to laparoscopic partial neph-
rectomy (LPN) with low overall morbidity, faster post-
operative recovery [2], and comparable oncological out-
comes [3]. With the widespread adoption of the da Vinci 
Surgical System (Intuitive Surgical, Sunnyvale, CA, USA), 
robotic partial nephrectomy (RPN) is rapidly emerging as 
an alternative to traditional LPN. Recently, laparoendo-
scopic single-site (LESS) PN was introduced. 
　The objective of this article was to review the efficacy of 
PN by several modalities and to analyze the current role 
of PN.
HISTORY
1. Chronic kidney disease and overall survival
Historically, when RN was the standard treatment for kid-
ney cancer, PN was performed only in the patient who had 
a tumor in a solitary kidney, a bilateral renal tumor, or re-
nal function impairment [4,5]. The main purpose of PN for 
these patients was the preserving of renal function, even 
though it was not enough. PN for the patient with a normal 
contralateral kidney is based on the concept that it provides 
an advantage over RN in preventing chronic kidney disease 
(CKD) by preserving more nephron capital. The relation-
ship between nephron mass reduction and accelerated kid-
ney damage was reported in experimental models [6,7]. Korean J Urol 2011;52:301-309
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TABLE 1. Overall survival of radical nephrectomy and partial nephrectomy　
　
Huang et al [8]  Thompson et al [10] Zini et al [16]
　 All patients ＜65 years Unmatched grade
b Matched grade
Nephrectomy
　RN 2,547 290 140 5,616 3,166
　PN    556 358 187 2,153 1,283
Death (%)
　RN 782 (32.1) 84 (29) 30 (21.4) _ _
　PN 110 (19.8) 62 (17.3) 13 (7) _ _
3-yr survival rate (%)
　RN 87 _ _ _ _
　PN 80 _ _ _ _
5-yr survival rate (%)
　RN 74 _ _ 71.3 70.9
　PN 68 _ _ 89.3 88.9
10-yr survival rate (%)
　RN _ _ 82 68.2 68.8
　PN _ _ 93 84.4 85.5
Univariate analysis
a
　HR   1.46 1.12 _ _ _
　p-value ＜0.001 0.52 _ _ _
Multivariate analysis
a
　HR   1.38 _ 2.16 1.23 1.19
　p-value ＜0.001 _   0.022   0.001   0.048
RN: radical nephrectomy, PN: partial nephrectomy, HR: hazard ratio, 
a: RN was associated with significant prediction of death from
any cause. 
b: analysis matched age, year of surgery, and tumor size except Furman grade
The clinical data also indicated that the independent pre-
dictor of postoperative renal function after PN was the 
amount of renal volume reduction or the percentage of re-
sected renal parenchyma [8-10]. 
　Patients with renal cell carcinoma (RCC) may have a risk 
for CKD because of the shared risk of hypertension, smok-
ing, diabetes, and advancing age [11,12]. Leaving this rela-
tion aside, recent studies reported a higher incidence of 
CKD after RN than after PN. A study by the MSKCC group 
of renal cortical tumors (≤4 cm) demonstrated that the 
3-year probability of freedom of new-onset mild CKD [glo-
merular filtration rate (GFR) ＜60 ml/min/1.73 m
2] was 80% 
after PN and 35% after RN, and that of moderate CKD (GFR 
＜45 ml/min/1.73 m
2) was 95% after PN and 64% after RN. 
RN was an independent risk factor for patients developing 
new onset of mild and moderate CKD in the multivariable 
analysis (hazard ratio [HR]: 3.82; 95% CI: 2.75-5.32; p＜ 
0.0001) [13].
　CKD is defined as either kidney damage for ≥3 months 
as confirmed by structural or functional abnormalities ma-
nifested by pathologic abnormalities or markers of kidney 
damage with or without decreased GFR, or a decrease in 
GFR ＜60 ml/min/1.73 m
2 for ≥3 months with or without 
kidney damage [14]. According to one study, CKD is an in-
dependent risk factor for the development of cardiovascular 
events, hospitalization, and death [15]. 
　Comparing RN with PN concerning the association with 
an increase in cardiovascular events and mortality for pa-
tients over 66 years of age, RN was associated with an in-
creased risk of overall mortality (HR: 1.38, p＜0.01) and a 
1.4 times greater number of cardiovascular events after 
surgery (p＜0.05), although RN was not significantly asso-
ciated with cardiovascular death (HR 0.95, p=0.84) [8]. 
Another study reported that PN had fewer adverse renal 
outcomes (16.4% vs. 21.8%; adjusted HR: 0.74; 95% CI: 
0.58-0.94), including a trend toward less frequent receipt 
of dialysis services, dialysis access surgery, or renal trans-
plantation than with RN. However, the likelihood of ad-
verse cardiovascular outcomes did not differ by treatment 
[9].
　The overall survival rate of RN is regarded to be lower 
than that of PN. A matched control study for age, year of 
surgery, tumor size, and Furman grade to assess the effect 
of nephrectomy type (RN vs. PN) on overall mortality 
showed that RN was associated with 1.19-fold (p=0.048) 
higher overall mortality rate [16]. Additionally, RN was 
significantly associated with death from any cause com-
pared with PN, especially in patients under 65 years of age 
(relative risk: 2.16, p=0.02) (Table 1) [10]. 
　The above studies suggest that PN is preferred for soli-
tary small RCC or suspicious RCC. However, because these 
studies were retrospectively designed, there are some 
limitations. Selection bias in deciding on the surgery type 
could exist. The methods of measuring preoperative and 
postoperative renal impairment were diverse [estimated 
GFR (eGFR), serum creatinine, proteinuria, and event of 
visiting dialysis center]. A randomized controlled trial is 
required. Korean J Urol 2011;52:301-309
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2. Misdiagnosis of renal mass
As imaging check-ups have become widespread, the in-
cidence of benign tumors confirmed during the operation 
that had been suspected as RCC is also increasing. Despite 
thorough preoperative radiological evaluation, 11% to 25% 
of presumed RCC were revealed to be benign in recent stud-
ies [17,18]. No imaging feature available currently can ac-
curately distinguish oncocytoma and small or lipid-poor 
angiomyolipoma from RCC. For these patients, PN is pre-
ferred to avoid useless nephrectomy and to preserve renal 
function.
CURRENT INDICATIONS 
Initially, PN was only accepted as the standard treatment 
of localized RCC in imperative or absolute indications 
(patients with an anatomically or functionally solitary kid-
ney or with bilateral RCC). Relative indications were those 
in which a functioning contralateral kidney was affected 
by comorbidities that might impair renal function in the fu-
ture, such as arterial hypertension, arteriosclerosis, and 
diabetes, including the hereditary forms of RCC. Elective 
indications were those in which the contralateral kidney 
was perfectly normal [19]. In the early days, elective PNs 
were performed restrictively in small, exophytic, and easily 
accessible tumors. Several articles reported long-term can-
cer-free survival rates of 92% to 100%. Therefore, PN be-
came one of the standard treatments for patients with clin-
ically localized RCC ＜4 cm (T1a tumors) in the 2007 RCC 
guidelines of the European Association of Urology [20].
　As surgeons’ experience has accumulated, attempts for 
larger, endophytic, and not easily accessible tumors have 
emerged. In a study of T1b RCC, PN and RN showed similar 
results for overall survival (92.3% vs. 87.8%, p=0.501), re-
current-free survival (92.3% vs. 77.8%, p=0.175), and cancer- 
specific survival (92.3% vs. 94.5%, p=0.936), respectively. 
Additionally, the proportion of patients with decreased re-
nal function (PN=0% vs. RN=11.5%) and postoperative 
changes in the serum creatinine level 1 year after neph-
rectomy (0.2±0.2 mg/dl vs. 0.3±0.5 mg/dl, p=0.150) was bet-
ter in the PN group than in the RN group [21]. In another 
study of T1b tumors, RN was associated with postoperative 
CKD in the multivariate analysis (odds ratio: 3.4; 95% CI: 
2.1-5.6). The survival analysis demonstrated that PN was 
associated with better overall survival (HR: 0.30; 95% CI: 
0.13-0.71; p=0.006) [22]. In the laparoscopic approach, com-
pared with LRN (n=75) and LPN (n=35) for T1b-T3N0M0 
RCC, overall mortality (11% vs. 11%), cancer-specific mor-
tality (3% vs. 3%), and recurrence (3% vs. 6%) rates (p=0.4) 
were equivalent. The postoperative decrease in the eGFR 
was less in the LPN group than in the LRN group at 13 and 
24 ml/min, respectively (p=0.03). Postoperatively, a two- 
stage increase in CKD stage occurred in 12% vs. 0% of pa-
tients in the LRN and LPN groups, respectively (p＜0.001). 
The data suggest that LPN for a large mass provides equiv-
alent oncologic efficacy and superior renal functional out-
comes compared with LRN [23]. 
　Concerning tumor location, Shikanov et al prospectively 
compared the outcomes of LPN for technically challenging 
tumors (endophytic tumors, tumors located near the hilum 
or the posterior upper pole) and tumors in other locations 
[24]. LPN for challenging tumors resulted in a higher rate 
of collecting system repair (78% vs. 61%, p=0.03). Howev-
er, operative [surgery time, warm ischemia time (WIT), 
blood loss, and intraoperative complications] and post-
operative (renal function, nadir hematocrit, complication 
rate, hospital stay, and positive margin rate) outcomes 
were similar between the groups. Therefore, with develop-
ing experience, LPN can be safe for technically challenging 
renal tumors in well-selected patients.
FUNCTIONAL OUTCOMES
Different surgical techniques can be used to perform PN, 
but all of them require adherence to basic principles of early 
vascular control, avoidance of ischemic renal damage with 
complete tumor excision with free margins, precise closure 
of the collecting system, careful hemostasis, and closure 
with or without tamponading of the renal defect with ad-
jacent fat, fascia, or any available artificial sealant [25,26]. 
Surgeons performing this approach require an under-
standing of renal responses to warm ischemia (WI) and 
available methods of protecting the kidney when the period 
of arterial occlusion exceeds normal parenchyma toler-
ability [27]. Although the historically safe duration of WIT 
from an experimental study, where full recovery of renal 
function is expected, is commonly thought to be 30 minutes, 
there are several limitations regarding functional data 
from the current literature [25]. Additionally, most func-
tional study data were based on serum creatinine reporting 
that PN does not have an effect on renal function [28,29], 
which is a limited biomarker for GFR. Unfortunately, there 
have been significant variations in the impact of WI on re-
nal function owing to various study protocols, possibly in-
volved in the renal function, including solitary kidney, 
pneumoperitoneal effect, estimation methods of renal 
function, and preoperative renal function [28,30]. Further-
more, few studies in the PN literature have successfully 
been able to measure functional compensation by a normal 
contralateral kidney or a functional decrease specifically 
in the operated kidney.
　A recent multi-institutional study provided 5-year renal 
functional outcomes in open partial nephrectomy (OPN) 
and LPN. Mean WIT was 30.7 and 20 minutes in the LPN 
and OPN groups, respectively. CKD, defined as preoperative 
serum creatinine greater than 2.0 mg/dl, was present at a 
rate of 1.6% and 6.4% in the LPN and OPN groups, respec-
tively. Postoperatively, the incidence of acute renal injury 
was 0.9% in each group. These data support that 30 minutes 
of WIT were safe for patients with normal preoperative re-
nal function [2]. Nonetheless, in patients with a contra-
lateral normal functioning kidney, which might play a buf-
fer role for the functional damage generated by the pro-
longed ischemia, the function of each kidney should be sep-Korean J Urol 2011;52:301-309
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arately evaluated to adjust for the compensation of the con-
tralateral kidney. A recent study with separate functional 
evaluation of each kidney demonstrated that prolonged WI 
over 28 minutes resulted in significant functional loss of 
the affected kidney at 3 months after surgery [31]. In addi-
tion, an international expert panel [32] strictly recommen-
ded that WIT should be kept to even ＜20 minutes and that 
in difficult cases cold ischemia should be started immedi-
ately but should not exceed 35 minutes. Therefore, the up-
per limit of the ischemic time that minimizes renal functio-
nal deterioration remains controversial to date. Moreover, 
there are still debates in human investigations regarding 
whether the ischemic damage to the affected kidney would 
be recoverable or whether the damage would be permanent 
even if WIT is prolonged. From previous large studies sug-
gesting that PN is associated with an increased risk of 
short- and long-term renal consequences, it is possible that 
prolonged WI might result in irreversible renal damage for 
a solitary human kidney [33,34]. Porpiglia et al assessed 
kidney damage in 18 patients with a normal contralateral 
kidney 1 year after LPN with a WIT between 31 and 60 mi-
nutes [35]. They suggested that mild recovery of the oper-
ated kidney was found 1 year after surgery, even with pro-
longed WI with 99mTc-MAG3 scan. Thus, it would be wor-
thy to separately investigate the functional changes in the 
affected kidney from total renal function with longer ob-
servation periods in patients with a normal contralateral 
kidney to answer this question. Surgeons should exert ex-
treme efforts to keep WIT as short as possible. When WIT 
is expected to exceed 30 minutes, an additional method 
such as renal hypothermia should be considered.
TECHNICAL ADVANCEMENTS AND OUTCOMES
1. Open partial nephrectomy and laparoscopic partial 
nephrectomy
1) Approach: Technically, the retroperitoneal approach is 
usually preferred for OPN. For LPN, the retroperitoneal 
approach was associated with decreased operative time 
(3.5 vs. 5.4 h, p＜0.01), blood loss (192 vs. 403 ml, p＜0.01), 
and discharge home (2.3 vs. 3.6 days, p＜0.01), with a sim-
ilar WIT compared with the transperitoneal approach, re-
spectively [36]. Therefore, except for anterior superior and 
medial masses, retroperitoneal access offered a superior 
approach. Despite these results, the transperitoneal ap-
proach is favored in many centers for LPN, because of the 
broad suturing space and ability to access tumors in any 
location with full renal mobilization. Gill et al reported that 
ease of clamping and unclamping of the hilum by virtue of 
Satinsky access through the transperitoneal approach al-
lowed them to implement the early unclamping technique, 
which dramatically improved WIT from 31.9 minutes to 
14.4 minutes in LPN [37].
2) Hilar control: In small and peripheral tumors, manual 
compression or application of a Kauffman clamp on the re-
nal parenchyma can be sufficient to reduce bleeding during 
resection in up to 50% of cases [38,39] of OPN. Renal hilar 
vessel clamping is carried out in 50% to 99% of patients in 
OPN [2,39-41]. On the other hand, to resect a tumor in a 
bloodless field and get better outcomes, routine hilar clam-
ping was recommended in LPN [38,39]. Nowadays, LPN 
without hilar clamping has been tried in selected cases and 
has been reported to be feasible [42,43]. 
3) Perioperative outcomes: The perioperative outcomes of 
LPN tend to be superior to those of OPN. LPN was asso-
ciated with shorter operative time, decreased operative 
blood loss, and shorter hospital stay (p＜0.01) with the 
analysis of 1,800 OPN and LPN cases for single T1 renal 
tumors. Another multicenter study that analyzed the peri-
operative data of OPN and LPN performed for 10 years 
demonstrated that the operative time was longer (221 vs. 
184 minutes) but estimated blood loss was less (293 vs. 418 
cc) and transfusion incidence was lower in the LPN group 
(p＜0.01). The margin-positive rate was comparable in the 
two groups [44]. The other matched-pair study of OPN and 
LPN reported that the operative time was shorter (84 
vs.150 minutes) and hospitalization time was shorter (5 vs. 
7 days) in the LPN group. The margin positive rate and de-
cline in the percentage of baseline hemoglobin were com-
parable in both groups [45]. The recently reported mar-
gin-positive rate of LPN was 0.6% [37]. 
4) Functional outcomes and complications: LPN was con-
sidered to have similar or longer ischemic times and more 
perioperative complications. In a large multicenter study, 
LPN was associated with longer ischemia time (p＜0.01) 
and more postoperative complications, particularly uro-
logical (p＜0.01). However, the chance of intraoperative 
complications was comparable. Renal functional outcomes 
were similar 3 months after LPN and OPN with 97.9% and 
99.6% of renal units retaining function, respectively [2]. In 
a matched-pair single-center study that compared 100 
OPN and LPN cases, the overall complication rate of the 
LPN group (19%) was comparable to that of the OPN group 
(14%), but intraoperative complications were higher in the 
LPN group (10% vs. 3%) [45]. In a study that compared the 
renal function of the solitary kidney after OPN and LPN, 
the risk of complications following LPN was 2.54 times that 
after OPN with a postoperative need for dialysis of 0.6% vs. 
10%, respectively [46]. In the Korean multicenter study, 
the decline of eGFR at the last available follow-up was sim-
ilar in the OPN and LPN cohorts, whereas the OPN cohort 
demonstrated shorter ischemic times [44]. 
　However, with simplifying renorrhaphy such as not us-
ing bolster [47], using an initial running hemostatic suture 
under ischemic conditions, reserving thorough paren-
chymal ligation and pelvicaliceal repair after hilar un-
clamping [48], and combined technique [37], the median 
WIT has decreased to 14.4 minutes in recent studies. As the 
WIT decreased, the postoperative renal function of LPN 
improved. In the most recent series, Gill et al divided 800 
cases of a single surgeon’s experience into 3 eras and com-
pared the perioperative and postoperative outcomes. 
When comparing era one to three, WIT was shorter (31.9, 
31.6, and 14.4 minutes, respectively, p＜0.01), and the Korean J Urol 2011;52:301-309
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FIG. 1. Procedures of robotic partial nephrectomy. (A) Marking renal arteries with vessel loops. (B) Confirming the endophytic tumor with
intraoperative ultrasound. (C) Clamping renal arteries with bulldog clamps. (D) Resection of tumor. (E, F) Sliding-clip renorrhaphy.
overall rates of postoperative and urological complications 
were significantly lower in the most recent era despite in-
creasing tumor complexity. Renal function outcomes were 
superior in era 3, as reflected by a lesser decrease in the esti-
mated GFR (18%, 20%, and 11%, respectively) [37].
5) Oncological outcomes: The reported oncological outcome 
of both OPN and LPN is similarly excellent. In the recent 
data, 3-year cancer-specific survival for patients with a sin-
gle cT1N0M0 RCC was similar, 99.3% and 99.2% after LPN 
and OPN, respectively [2]. A multicenter study also demon-
strated that OPN and LPN showed similar 5-year re-
current-free survival [44]. In the long-term data, both sur-
geries also provided similar long-term overall and can-
cer-specific survival in patients and similar 7-year meta-
stasis-free survival (97.5% vs. 97.3%) after LPN and OPN, 
respectively [3]. 
2. Robotic partial nephrectomy
Although LPN has proved to be a worthy alternative with 
similar oncological outcomes [3] with lower morbidity and 
faster postoperative recovery [2], much experience is re-
quired to perform the surgery for adequate WIT and to get 
those results. A new alternative is RPN. Since the Da Vinci 
Surgical System (Intuitive Surgical, Sunnyvale, CA, USA) 
was introduced, it has become widespread because of its 
shorter learning curve than the laparoscopic approach. 
Now, it is well established for performing radical prosta-
tectomy. As experience is accumulated, the indication of ro-
botic surgery is expanding to PN [49]. Generally, the in-
dications for RPN are the same as for OPN and LPN [50]. 
Recently, the indications of RPN have also expanded to the 
multiple renal masses of hereditary kidney cancer patients 
[51] and the nononcologic field for pediatric RPN [52]. 
Technically, the transperitoneal approach is used in most 
RPN series and the retroperitoneal approach was recently 
introduced (Fig. 1). Hybrid laparoscopic-robotic technique 
was used in the earlier period. Recent series tend to be fully 
robotic [53]. Cabello et al describe their three-arm robotic 
technique with sliding-clip renorrhaphy [54]. The bedside 
assistant places a clip on the suture, which is then slid down 
by the console surgeon to obtain perfect tension. With this 
technique, the console surgeon can fully control the renor-
rhaphy and WIT can be shorter without knot tying [55]. 
RPN shows at least equal perioperative outcomes to LPN 
with shorter overall operative times and WIT as surgeons 
become more experienced. A positive surgical margin is 
rare (0-2.3%), and there has been only one reported re-
currence following RPN [56,57]. Postoperative renal func-
tion and oncological outcomes of RPN are comparable with 
the LPN series [58]. In recent series, complication rates 
have ranged from 0% to 17% with rare instances of open 
conversions. The most common complication is urine leak-
age [56]. Furthermore, recent reports have suggested that 
robot assistance confers a particularly strong advantage 
when attempting to address larger, complex lesions, in-
cluding those that are predominantly endophytic, cen-
trally located, or directly abutting the hilum (Table 2) [56, 
59-61]. However, RPN still has limitations. Robotic sur-
gery is more expensive than OPN and LPN in many coun-
tries because of the high cost of the Da Vinci robot and be-
cause the health care system does not cover it. Another limi-
tation is the requirement for an experienced bedside 
assistant. Generally, the role of the assistant is important 
during hilar clamping and releasing with the bulldog 
clamp or laparoscopic Satinsky. Although efforts to control 
the hilum by the console surgeon have emerged, such as the Korean J Urol 2011;52:301-309
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use of a fourth arm, it is more difficult than the three-arm 
approach owing to the crowding of the instruments. 
3. Laparoendoscopic single-site partial nephrectomy
LESS surgery is one of the innovations of laparoscopic sur-
gery. It can minimize patient discomfort and maximize the 
cosmetic benefit with one small incision. For a kidney tu-
mor, PN can get the advantage because of small specimen 
differ from RN. The reported WIT of LESS PN was 11 to 
29 minutes and that of hybrid robot-assisted LESS PN was 
16 to 43 minutes [62,63]. Because most surgeons do not 
have much experience, keeping the WIT short can be a 
burden. For this reason, some surgeons perform LESS PN 
without ischemia [64,65]. Mean operative time was com-
parable to RPN [50,62-66]. The most common complication 
was bleeding requiring transfusion [62-66]. Oncological 
outcomes are promising until cases accumulate. Although 
the feasibility has been proved, LESS PN is indicated only 
for small, exophytic, and easily approachable tumors. 
Wider experience and longer follow-up are necessary to es-
tablish the role of this technique. 
4. Other minimally invasive techniques
1) Radiofrequency ablation: Radiofrequency ablation (RFA) 
induces thermal damage by converting radiofrequency 
waves to heat. The goal of RFA is to induce a temperature 
of 50-100
oC throughout the tumor [67]. An open, laparo-
scopic, or percutaneous approach is possible depending on 
the tumor location. Over a mean follow-up period of 25 
months for small renal masses (mean size: 2.4 cm), the over-
all recurrence-free survival rate was 96.8%, the cancer- 
specific survival rate was 98.5%, and the overall survival 
rate was 92.3% [68].
2) Cryoablation: Cryoablation causes tumor destruction by 
a rapid freeze and thaw cycle at a temperature below minus 
20
oC [69]. For the anterior or medial aspect of the kidneys, 
the laparoscopic cryoablation (LCA) technique is better be-
cause these lesions are close to the bowel and other solid 
organs. In contrast, the percutaneous cryoablation (PCA) 
technique is preferred for tumors located on the posterior 
and lateral aspect due to ease of access through the skin 
[70]. The size and location are predictors of successful 
treatment. The overall survival rate of PCA was reported 
to be 92.6% with a cancer-specific survival rate of 100% at 
a mean follow-up of 22 months [71]. In 3-year follow-up data 
of LCA, 3-year cancer-specific survival was 98% [72]. The 
most common complications are pain and paresthesias at 
the operative site. Limitations are the lack of histologic con-
firmation of complete tumor ablation and the need for rig-
orous radiologic follow-up [69]. 
3) High-intensity focused ultrasound: High-intensity fo-
cused ultrasound (HIFU) generates high-intensity ultra-
sound waves that increase renal tissue temperatures to 
more than 65
oC, leading to tissue necrosis. At the molecular 
level, tissue damage is mediated by the two mechanisms 
of thermal and acoustic cavitation [73]. In early results that 
were confirmed by nephrectomy specimens after HIFU, 
15% to 35% of tissue damage was found in the targeted tis-
sue, which indicated incomplete ablations [74]. Additional-
ly, the tissue damage (interstitial hemorrhage, coagu-
lation necrosis, shrinkage of collagen fibers) did not corre-
late with the administered energy [75]. The reported side 
effects were grade 3 skin burns and thermal lesion of the 
small intestine due to poor focusing. Refinement of the 
technology is required. 
CONCLUSIONS
Currently, PN is considered a standard treatment for T1a 
tumors with the benefit of preventing CKD; improving 
overall survival, especially for the patients younger than 
65 years of age; and decreasing the overall mortality rate. 
For T1b tumors, more clinical data are required to establish 
the oncological and functional benefits of PN. LPN has 
come to represent comparable perioperative and onco-
logical outcomes in the recent era. The role of RPN is ex-
pected to expand to even complicated or challenging cases. 
The role of LESS PN is not yet established. Other ablative 
techniques can be indicated for patients who cannot toler-
ate the morbidity of conventional surgery and have a high 
risk of RCC recurrence, such as patients with von Hippel- 
Lindau syndrome.
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